ArticleFrontiers in pharmacology2025
Inverse association between pre-high-altitude potassium levels and coronary microvascular disease at high altitude: a case-control study.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Serum potassium and high-altitude coronary microvascular disease: a propensity score matched analysis revealing a linear dose-response relationship.Frontiers in pharmacology · 2026Article
- Correlation between calcium levels and coronary microvascular disease in high-altitude environments: nested case-control study.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: High-altitude hypoxia is known to impair cardiac microvascular function, a pathophysiological state recognized as coronary microvascular disease (CMVD). This study aimed to investigate the independent association between serum potassium levels and the risk of developing CMVD, after controlling for traditional cardiovascular risk factors such as hypertension, dyslipidemia, and smoking. Methods: This case-control study enrolled 1,175 trainees with long-term exposure to high altitude (≥3,000 m), comprising 235 patients with CMVD (cases) and 940 healthy controls. We employed multivariable logistic regression analysis to systematically evaluate the associations of traditional risk factors and serum potassium levels with the risk of CMVD. Results: A key finding from our analysis was a significant inverse association between serum potassium levels and the odds of CMVD (OR = 0.26; 95% CI, 0.14-0.47). Specifically, higher potassium concentrations were correlated with a substantially lower disease risk. This inverse association was more prominent in individuals with a moderate body mass index and in smokers. Conclusion: This is the first study to demonstrate that a higher serum potassium level is independently associated with lower odds of CMVD in populations exposed to high altitudes. This finding provides a new direction for developing targeted health screening and preventive strategies in high-altitude regions, holding significant potential for protecting specific at-risk groups such as individuals with a particular BMI, and smokers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.